Proactive Investors
21 Sept 2026, 07:13 UTC · 2h ago
Verdict
Headline takes no side. We score CLBX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Coiled Therapeutics has enrolled the first three patients each into two dose groups (120mg twice-daily and 160mg once-daily) for a reformulated version of its lead cancer drug AO-252.
Newpublished 21 Sep 2026
So whatSuccessful enrollment validates the switch to a lipid-based softgel to fix the 40% variance in benefit seen in earlier once-daily tablet trials.
More positive than 76% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
The company expects to dose up to 30 patients on the new formulation by the end of 2026.
Newpublished 21 Sep 2026
So whatReaching this 30-patient target by year-end is the primary catalyst for the upcoming phase I/II study expansion.
More positive than 62% of claims this week
Initial safety and pharmacokinetic data for the reformulated drug are expected by the end of 2026.
Newpublished 21 Sep 2026
So whatThis data print in Q4 2026 will determine if the softgel version achieves the 'predictable absorption' required to move into ovarian and prostate cancer trials.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
Share price jumped 6% after a study showed its Parsortix system can identify cancer drug targets that rivals missed.
More positive than 70% of ticker scores this week
The company has successfully enrolled the first patients into dose groups for its reformulated cancer drug, de-risking its strategy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
3d ago
—
No price for CLBX right now — the quote feed didn't answer.
CLBX chart →
